Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data

S. Hallberg1 · S. R. Gandra2 · K. M. Fox3 · J. Mesterton1,4 · J. Banefelt1 · G. Johansson5 · L.-Å. Levin6 · P. Sobocki4,7

Received: 4 February 2015 / Accepted: 27 May 2015 / Published online: 16 June 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Objectives To estimate healthcare costs of new cardiovascular (CV) events (myocardial infarction, unstable angina, revascularization, ischemic stroke, transient ischemic attack, heart failure) in patients with hyperlipidemia or prior CV events.

Methods A retrospective population-based cohort study was conducted using Swedish national registers and electronic medical records. Patients with hyperlipidemia or prior CV events were stratified into three cohorts based on CV risk level: history of major cardiovascular disease (CVD), coronary heart disease (CHD) risk-equivalent, and low/unknown risk. Propensity score matching was applied to compare patients with new events to patients without new events for estimation of incremental costs of any event and by event type.

Results A CV event resulted in increased costs over 3 years of follow-up, with the majority of costs occurring in the 1st year following the event. The mean incremental cost of patients with a history of major CVD (n = 6881) was €8588 during the 1st year following the event. This was similar to that of CHD risk-equivalent patients (n = 3226; €6663) and patients at low/unknown risk (n = 2497; €8346). Ischemic stroke resulted in the highest 1st-year cost for patients with a history of major CVD and CHD risk-equivalent patients (€10,194 and €9823, respectively); transient ischemic attack in the lowest (€3917 and €4140). Incremental costs remained elevated in all cohorts during all three follow-up years, with costs being highest in the major CVD history cohort.

Conclusions Healthcare costs of CV events are substantial and vary considerably by event type. Incremental costs remain elevated for several years after an event.

Keywords Cardiovascular · Costs · Hyperlipidemia · CVD · Resource use · Burden of illness

JEL Classification I12

Introduction

Cardiovascular disease (CVD), with the usual underlying pathology of atherosclerosis, is a major cause of premature death worldwide and a substantial source of disability. Consequently, CVD contributes extensively to the escalating costs of healthcare [1]. The most common manifestation of CVD is coronary heart disease (CHD). CHD has been estimated to be the leading cause of disability in Europe, accounting for approximately 10% of total disability-adjusted life years [2].
There are several recent studies that have examined the costs of CVD-related events, and especially so with a focus on short-term healthcare costs due to CVD-related events [3–10]. These studies have not included patients based on a diagnosis of or treatment for hyperlipidemia but instead included patients hospitalized for CV events [3, 10, 11], patients with atherosclerosis [4], hypertension [5], or acute coronary syndrome [6, 7, 12], or used a prevalence-based approach [8, 9]. Only a few studies have examined the long-term costs associated with CVD-related events [3, 10, 11] and stratified by specific event types [13]. There are limited data that have focused on costs of CVD-related events over the acute phase, short term and long term for hyperlipidemia patients specifically. Also, estimates of the cost of recurrent and subsequent CV events are limited; previous studies have focused on the first CV event and limited the study cohorts to those without CVD at baseline.

The present study contributes to filling the gap in available evidence in the area by providing acute, short-term and long-term direct incremental costs in hyperlipidemia patients. In addition, costs stratified by CV event type and costs of subsequent CV events are provided. These costs may serve as an important basis for health economic analysis to estimate the cost-effectiveness of health technologies aimed at preventing CVD-related events.

The objective of the study was to characterize the use of healthcare resources and to estimate the acute (first 30 days), the short-term (1st year), and long-term (up to 3 years) healthcare costs of new CV events (myocardial infarction, unstable angina pectoris, revascularization [percutaneous transluminal coronary angioplasty], ischemic stroke, transient ischemic attack, or heart failure) in patients with hyperlipidemia or a history of CV events.

Methods

Study design and population

This was a retrospective register study based on a matched control design. The primary data sources for the study were electronic medical records in primary care and three selected national compulsory health registers which are governed by the National Board of Health and Welfare. By merging data from the medical records with data from the National Patient Register, the Cause of Death Register, and the Swedish Prescribed Drug Register, information on a patient-related basis was available for the following resource and cost domains:

- Pharmaceuticals: the Prescribed Drug Register collects data on the total costs associated with each filled prescription.
- Inpatient and outpatient care: all hospitalizations, surgical procedures, and outpatient specialist visits were collected from the National Patient Register for the complete observable period for each patient.
- Primary care: all physical contacts and contacts by phone with nurses, general practitioners, and other healthcare personnel in the primary care centers were collected.
- Death: the Cause of Death Register provided confirmed dates of death, allowing for censoring of patients.

Unique individual patient ID numbers were available in all data sources which allowed for linkage of individual patients between data sets. The linkage of de-identified individual patients was performed by the National Board of Health and Welfare. The study was approved by the Swedish Ethics Review Board.

Patients were included in the study population based on having hyperlipidemia, defined as treatment with lipid-lowering therapy (LLT) as this is the most accurate way of identifying hyperlipidemia patients in Sweden. Patients were included on the date of the first prescription of LLT during 2006 if a second filled prescription followed within 6 months. The study inclusion date was defined as the date of the first of the filled prescriptions for LLT. Additionally, patients without LLT during 2006 but with a prior history of CV events (within the past 5 years) were also included in the study in order to capture patients with CVD at baseline. For patients that did not receive LLT but who had a history of CV events, the study inclusion date was defined as January 1, 2006.

Patients were stratified into three separate cohorts based on CVD risk according to the National Cholesterol Education Program Adult Treatment Panel III guidelines [14] and the European Society of Cardiology guidelines [15] from 10 years prior to and up until study inclusion. The purpose of the stratification was to analyze health resource utilization (HRU) and costs over different sub-groups of patients with varying risk of CVD. The stratification was done according to the following definitions:

1. History of major CVD cohort: prior diagnosis of myocardial infarction, unstable angina pectoris, ischemic stroke, or revascularization.
2. CHD risk equivalent cohort: patients not included in the history of major CVD cohort and with prior diagnosis of diabetes, peripheral artery disease, abdominal aortic aneurysm, transient ischemic attack, or stable angina pectoris.
3. Low/unknown risk cohort: patients not included in the history of major CVD cohort or CHD risk equivalent cohort.

Patients were observed from study inclusion until December 31, 2009 for identification of new CV events (exposure time). The first new CV event during this period was defined as the index date. Patients were followed for 3 years (up until December 31, 2012) after the index date (or until death, whichever occurred first) for identification of HRU related to CV events on an individual patient level.

Direct costs were estimated based on HRU related to a new CV event which consisted of the number of healthcare visits, hospitalization days, surgical procedures, and pharmaceutical use on an individual patient level. Hospitalizations, procedures or healthcare visits were required to have an accompanying primary diagnosis or any surgery code of a CV event and pharmaceuticals were required to be LLT in order to be defined as related to CV events. Costs were based on a review of Swedish regional price lists from 2012 from different healthcare regions in Sweden [16–21]. Cost outcomes were calculated for the following time periods:

1. 365–1 days before new CV event (pre-index period),
2. 0–30 days after new CV event (acute period),
3. 0–365 days after new CV event (short term),
4. 366–730 days after new CV event, and
5. 731–1095 days after new CV event (long term).

Statistical analysis

In order to estimate HRU and costs of new CV events, a comparison between patients with and without a new CV event within each CVD risk level was conducted. To control for confounders and limit bias, propensity score matching was applied. Patients without a CV event between study inclusion and December 31, 2009 within each CVD risk level were matched to patients with a CV event within the same CVD risk category based on a 1:1 match without replacement. The covariates included in the matching were age, gender, Charlson comorbidity index, hospital visits related to CV events during the 1-year period prior to study inclusion, and days of hospitalization related to CV events during the 1-year period prior to study inclusion. The propensity score was estimated using logistic regression and the caliper approach was used for matching. The caliper method uses a tolerance level of the maximum propensity score distance to avoid the risk of bad matches. The maximum propensity score distance was set to a fourth of the standard deviation of the propensity score. The index date for patients without a new CV event was set to the index date of the patient to whom they were matched. The quality of the matching was evaluated by investigating the standardized differences between cases and matched controls in the variables used in the matching. An ex-ante limit of 10 % in standardized differences was set for all variables used in the matching.

Costs were estimated by multiplying each resource use with the corresponding average unit cost from the price lists. All costs were converted to 2012 euro (€) from 2012 Swedish kronor (conversion rate: 1 euro = 8.71 Swedish kronor [22]). Incremental costs associated with a new CV event were calculated as the mean difference in costs between the matched patients with and without new CV events within each cohort.

The non-parametric Wilcoxon signed-ranked test was used to test for statistical significance in differences in costs between patients with new events and matched patients without events, for each time period and each cohort.

All data management and statistical analysis was performed using MySQL and Stata 12.

Results

Patient attrition and characteristics

A total of 96,256 patients were identified for inclusion in the study. Of these, 14,008 (14.6 %) experienced a CV event during exposure time. Outcomes were assessed for the 12,604 (90.0 %) patients for whom a match could be found based on characteristics at study inclusion. Cases (i.e., patients with a new event during exposure time) and matched controls (i.e., patients without a new event during exposure time) were followed for calculation of HRU and costs in parallel from the index date.

Among patients with new CV events, 6881 of the included patients had a history of major CVD. 3226 patients belonged to the CHD risk equivalent cohort and the remaining 2497 patients to the low/unknown risk cohort (Fig. 1). Equally many patients without new CV events were included as controls, making the total cohort sizes twice as large (13,796 patients in the history of major CVD, 6448 patients in the CHD risk equivalent cohort and 4994 patients in the low/unknown risk cohort). The characteristics of the different cohorts at index date are presented in Table 1, stratified by patients with and without new CV events.

Many of the patterns between cases and controls were seen in all three cohorts. Cases and controls in all risk cohorts were relatively balanced in terms of demographic and background characteristics, although cases were slightly more comorbid than the controls at index. There did not appear to be any systematic differences between
Patients ≥18 years of age who met the inclusion criteria

| Patients with history of major CVD | CHD risk equivalent patients | Patients with low/unknown risk |
|-----------------------------------|-----------------------------|-------------------------------|
| n = 33,429                        | n = 23,561                  | n = 32,266                    |

Patients with a new CV event during exposure time

| Patients with history of major CVD | CHD risk equivalent patients | Patients with low/unknown risk |
|-----------------------------------|-----------------------------|-------------------------------|
| n = 7,847                         | n = 3,522                   | n = 2,639                     |

Patients with a new CV event who were matched to patients without a new CV event

| Patients with history of major CVD | CHD risk equivalent patients | Patients with low/unknown risk |
|-----------------------------------|-----------------------------|-------------------------------|
| n = 7,846                         | n = 3,509                   | n = 2,631                     |

Patients with a new CV event whose matched control was still alive at the index date

| Patients with history of major CVD | CHD risk equivalent patients | Patients with low/unknown risk |
|-----------------------------------|-----------------------------|-------------------------------|
| n = 6,881                         | n = 3,226                   | n = 2,497                     |

Fig. 1 Patient attrition

cases and controls in LLT around the time of index for patients with a history of major CVD. For the other cohorts, a higher share of controls was on LLT compared to cases in the same cohort.

Patients with a history of major CVD were older and more comorbid compared to the other cohorts. Despite this, the history of major CVD cohort had the lowest share of patients on LLT amongst the three risk cohorts.

Health resource utilization and associated costs

Days of CV-related hospitalization, number of CV-related outpatient visits, and number of primary care contacts are presented as separate categories of HRU (Table 2).

Cases and controls were somewhat unbalanced at index date, as HRU during the pre-index period (365–1 days before the new CV event) was higher among cases than controls for all categories, despite having been matched on outpatient specialist visits and days of hospitalization during the 1-year period prior to study inclusion. There was a sharp increase among cases in all categories of HRU during the 1-year period after index for the history of major CVD cohort, with the exception of primary care contacts. Notably, the mean number of hospitalization days in the history of major CVD cohort increased from 1.37 during the 1-year period before index date to 9.70 during the year after index. This increase was also seen in the CHD risk equivalent (from 0.32 to 9.64 days) and low/unknown risk cohorts (from 0.34 to 8.84 days). There was no such corresponding increase seen among controls in any of the three cohorts, as HRU of controls was, in general, stable across all periods.

Total costs associated with new CV events are presented in 2012 euro and by risk cohort for all time periods (Table 3).

The mean costs of HRU were higher for cases than for matched controls across all time periods and cohorts, including in the pre-index period. This difference was small in the CHD risk equivalent cohort, however (a difference of €148 in the pre-index period compared to €589 in the history of major CVD cohort and the low/unknown risk cohort, respectively). A sharp increase in mean costs of cases in all cohorts could be seen right after the index event with acute costs in the range of €6397–€6524, after which costs decreased during the subsequent years. No corresponding increase was observed in controls, with mean costs of controls remaining relatively stable during the entire 3-year period. The short-term costs of patients with new events were similar across the three cohorts (costs in the range of €8925–€9811).

The long-term costs were also similar in the history of major CVD and CHD risk equivalent cohorts (€2384 and €2474, respectively) but lower for the low/unknown risk cohort (€1771). Costs remained elevated 2–3 years after index compared to the pre-index period in all three cohorts. The history of major CVD cohort saw the greatest regression toward levels close to those seen before index (the difference between pre-index and long-term costs was €165 for cases in the history of major CVD cohort; corresponding figures for the CHD risk equivalent and low/unknown risk cohort were €985 and €742, respectively).

The incremental costs between matched patients with and without new CV events were found to be statistically significant in all time periods for all cohorts (Table 3). The incremental mean cost during the 1st year following a new CV event was €8588 for patients with a history of major CVD, similar to the cost of patients in the CHD risk equivalent cohort (€8663) and higher than the cost of the low/unknown risk cohort (€7901). Patients in the history of major CVD cohort had the highest incremental costs during both the 2nd and 3rd year after a new CV event (€1733 and €1328, respectively). The CHD risk equivalent cohort had higher incremental costs than the low/unknown risk cohort during the 2nd year (€1523 vs €1162), whilst the
incremental costs during the 3rd year following a new CV event became more alike (€1014 for the CHD risk equivalent and €990 for the low/unknown risk cohort).

Total costs of HRU following a new event were also analyzed by type of new event (Table 4). Similar cost patterns for different event types were seen for the history of major CVD and CHD equivalent cohorts (Table 4). With regard to short-term costs (the 1st year after index), the order of the three most costly event types was identical in the history of major CVD and CHD risk equivalent cohort: ischemic stroke (incremental costs for the history of major CVD and CHD risk equivalent cohort were €10,194 and €9823, respectively), myocardial infarction (€8801 and €9807), and revascularization (€8504 and €8795). Transient ischemic attack was the least costly event type for both cohorts (€3917 and €4140). A dissimilarity between the two cohorts was observed for long-term costs (731–1095 days after index) as heart failure was associated with almost twice as high costs in the history of major CVD cohort as in the CHD risk equivalent cohort (€2344 vs €1220). Heart failure was, however, the most costly event type for both cohorts in the long term.

**Subsequent events—health resource utilization and associated costs**

Subsequent events were common amongst the study population, with 33% of patients experiencing a second event.

| Table 1 Patient baseline characteristics at index date for cases (matched patients with new cardiovascular events) and controls (matched patients without new cardiovascular events) | Patient baseline characteristics | Cases | Controls |
|---|---|---|---|
| History of major CVD cohort (n = 6881) | Mean age (SD) | 75.26 (11.03) | 75.36 (10.86) |
| | Gender (% females) | 39.2 | 38.8 |
| | Mean days of follow-up (SD) | 741 (430) | 741 (430) |
| | Mean Charlson comorbidity index (SD)* | 2.81 (2.11) | 2.62 (2.12) |
| | Myocardial infarction (%)* | 43 | 38 |
| | Peripheral vascular disease (%)* | 15 | 11 |
| | Cerebrovascular disease (%)* | 42 | 46 |
| | Diabetes mellitus (%)* | 25 | 21 |
| | Lipid-lowering therapy (%) | 63.2 | 62.3 |
| | Statin treatment (%) | 60.0 | 59.7 |
| CHD risk equivalent cohort (n = 3226) | Mean age (SD)** | 74.47 (10.29) | 74.61 (10.38) |
| | Gender (% females) | 43.6 | 43.1 |
| | Days of follow-up (SD) | 800 (413) | 800 (413) |
| | Mean Charlson comorbidity index (SD)* | 2.59 (2.12) | 2.39 (2.12) |
| | Myocardial infarction (%)* | 1 | 0 |
| | Peripheral vascular disease (%)* | 18 | 14 |
| | Cerebrovascular disease (%)* | 20 | 17 |
| | Diabetes mellitus (%) | 41 | 41 |
| | Lipid-lowering therapy (%)* | 78.8 | 83.1 |
| | Statin treatment (%)* | 74.6 | 78.8 |
| Low/unknown risk cohort (n = 2497) | Mean age (SD)*** | 73.09 (11.00) | 73.30 (10.96) |
| | Gender (% females) | 46.3 | 46.0 |
| | Days of follow-up (SD) | 856 (391) | 856 (391) |
| | Mean Charlson comorbidity index (SD)* | 1.20 (1.55) | 1.04 (1.56) |
| | Myocardial infarction (%)** | 1 | 0 |
| | Peripheral vascular disease (%)** | 4 | 3 |
| | Cerebrovascular disease (%)* | 9 | 6 |
| | Diabetes mellitus (%)* | 4 | 2 |
| | Lipid-lowering therapy (%)* | 73.8 | 80.2 |
| | Statin treatment (%)* | 69.9 | 75.8 |

* p value <0.01, ** p value <0.05, *** p value <0.10
within 2 years after index. Patients who had heart failure as an index event had by far the highest frequency of experiencing a subsequent event (43 %), with heart failure being the most common event type (33 % of the patients who experienced heart failure as an index event had a subsequent heart failure hospitalization). This is in line with the finding that heart failure was associated with the highest long-term costs. Conversely, revascularizations were associated with the lowest frequency of a subsequent event, with 77 % of patients with revascularization as an index event experiencing no subsequent event during 2 years following the procedure. This also aligns with revascularizations being associated with comparatively lower costs in the long term.

The healthcare costs of patients who experienced at least two new CV events were evaluated for patients in all cohorts (n = 4514). The index date in these analyses was set to the date of the second CV event. The pre-index costs were thus high (€6396) since they included some costs from the first CV event. Despite the high pre-index costs, a sharp increase was still observed after the second event (acute costs during the 1st month after the second event were €6416). Costs gradually decreased during subsequent years after the second event (€6457). In the longer-term, costs decreased quite rapidly but remained at higher levels compared to patients with one or two new CV events (€3715 and €3224 for the 2nd and 3rd year, respectively).

Corresponding analyses for patients who experienced at least three new events during time of exposure were also performed (n = 1741). The index date was set to the date of the third event in these analyses. The pre-index costs were even higher among these patients (€9879), but the short-term costs after the third new CV event were still similar to those observed after the first or second new event (acute costs during the 1st month after the second event was €6457). In the longer-term, costs decreased quite rapidly but remained at higher levels compared to patients with one or two new CV events (€3715 and €3224 for the 2nd and 3rd year, respectively).

**Discussion**

There are several studies that have examined costs of CV events with a focus on short-term costs and/or first CV event. However, data are limited for long-term costs and especially for patients experiencing a subsequent CV event. There are also limited data that have focused on cost of CVD-related events over the acute phase, short term and long term for hyperlipidemia patients specifically.

This study demonstrated the substantial acute and short-term costs associated with new CV events, thereby confirming results by recent studies on the economic burden of CV events [3, 4, 6, 10]. The increase in costs just after the

### Table 2: Mean health resource utilization for cases (matched patients with new cardiovascular events) and controls (matched patients without new cardiovascular events)

| History of major CVD cohort | CHD risk equivalent cohort | Low/unknown risk cohort |
|-----------------------------|---------------------------|------------------------|
| Mean HRU (SD)               | Mean HRU (SD)             | Mean HRU (SD)          |
| n  | Cases | Controls | n  | Cases | Controls | n  | Cases | Controls |
|-----------------------------|---------------------------|------------------------|
| Hospitalization (days)      |                           |                        |
| 365–1 days before new CV event | 6881 1.37 (5.76) 0.91 (4.94) | 3226 0.32 (2.29) 0.16 (1.69) | 2497 0.34 (2.62) 0.13 (1.69) |
| 0–365 days after new CV event | 6881 9.70 (11.20) 0.17 (2.43) | 3226 9.64 (11.91) 0.07 (1.20) | 2497 8.85 (11.15) 0.03 (0.54) |
| 366–730 days after new CV event | 6251 1.92 (7.91) 0.14 (1.60) | 2995 1.84 (7.57) 0.08 (1.18) | 2331 1.15 (5.01) 0.10 (1.49) |
| 731–1095 days after new CV event | 4987 1.62 (6.33) 0.32 (2.84) | 2465 1.36 (5.50) 0.34 (3.64) | 2031 1.06 (5.10) 0.18 (1.76) |
| Outpatient (visits)         |                           |                        |
| 365–1 days before new CV event | 6881 0.12 (0.54) 0.06 (0.38) | 3226 0.09 (0.39) 0.04 (0.55) | 2497 0.10 (0.45) 0.03 (0.25) |
| 0–365 days after new CV event | 6881 0.22 (0.78) 0.02 (0.23) | 3226 0.28 (1.15) 0.02 (0.16) | 2497 0.27 (0.68) 0.01 (0.16) |
| 366–730 days after new CV event | 6251 0.13 (0.54) 0.03 (0.22) | 2995 0.14 (0.57) 0.02 (0.15) | 2331 0.18 (1.67) 0.02 (0.16) |
| 731–1095 days after new CV event | 4987 0.09 (0.42) 0.03 (0.36) | 2465 0.11 (0.45) 0.02 (0.17) | 2031 0.10 (0.44) 0.02 (0.17) |
| Primary care (contacts)     |                           |                        |
| 365–1 days before new CV event | 6881 2.19 (4.19) 1.88 (3.61) | 3226 2.65 (4.64) 2.21 (3.97) | 2497 1.85 (3.95) 1.47 (3.09) |
| 0–365 days after new CV event | 6881 1.93 (4.15) 1.50 (3.37) | 3226 2.44 (4.57) 1.86 (3.42) | 2497 1.87 (3.97) 1.30 (2.91) |
| 366–730 days after new CV event | 6251 1.91 (4.03) 1.66 (3.44) | 2995 2.30 (4.44) 2.15 (3.77) | 2331 1.79 (4.00) 1.46 (3.22) |
| 731–1095 days after new CV event | 4987 1.78 (3.97) 1.57 (3.41) | 2465 2.20 (4.68) 2.01 (3.63) | 2031 1.66 (3.86) 1.34 (2.98) |
index event was observed regardless of patients’ CV risk level at study inclusion. Confounders are minimized by applying a matched control design and focusing on incremental costs between patients with new CV events and patients without new events. It should be borne in mind when interpreting the results that the observed HRU and associated cost of the controls are largely driven by study design and cohort definitions. For instance, patients in the history of major CVD cohort were required to have an event within 5 years of study inclusion, after which the patients defined as controls did not experience another event during the exposure time. These definitions have likely affected the observed cost pattern for controls in the history of major CVD cohort.

The results also indicated that a patient’s first CV event leads to substantial long-term costs, as only the history of major CVD cohort returned to levels close to those seen in the pre-index period 2–3 years after the index date, with costs remaining elevated in the CHD risk-equivalent and low/unknown risk cohorts. The finding that greater CV risk-level at baseline resulted in higher long-term costs is consistent with recent studies which have shown that follow-up costs after a CV event are greater if patients had a comorbidity such as diabetes before the new event [3, 11].

The study also presents healthcare costs associated with CVD-related events stratified by specific event types, which only a few studies have examined before. The findings of the study demonstrate the variation in healthcare cost of different types of events, both in the short term and in the long term. An older study by Zethraeus et al. [13] on CHD and stroke also found a variation in costs by event type and that ischemic stroke was the event type associated with the highest short-term costs which is in line with the results from this study. Transient ischemic attack was associated with the lowest short-term costs in this study, across all risk cohorts.

Of all studied event types, heart failure seemed to be associated with the greatest risk of experiencing a subsequent event and the highest long-term costs, while revascularization procedures were associated with the lowest risk of experiencing a subsequent event and lowest long-term costs. One third of the patients with new CV events had at least one subsequent event during a 2-year period after the index event.

The high representativeness, large samples, long follow-up, and data quality that underlie the analyses of HRU and costs are important strengths of this study. Sweden is well known for having excellent registers with a high degree of validity and completeness that allow for generating real-

| Mean costs of HRU related to CV events in €, for all cohorts (SD) | n  | Cases     | Controls  | Incremental* |
|---------------------------------------------------------------|----|-----------|-----------|--------------|
| History of major CVD cohort                                  |    |           |           |              |
| 365–1 days before new CV event                               | 6881| 2219 (4722)| 1630 (4094)| 589 (5623)   |
| 0–30 days after new CV event                                 | 6881| 6459 (5471)| 94 (469)   | 6365 (5488)  |
| 0–365 days after new CV event                                | 6881| 9489 (8398)| 902 (2269) | 8588 (8624)  |
| 366–730 days after new CV event                              | 4987| 2672 (6367)| 940 (1836) | 1732 (6602)  |
| 731–1095 days after new CV event                              | 4154| 2384 (5157)| 1056 (2554)| 1328 (5772)  |
| CHD risk equivalent cohort                                   |    |           |           |              |
| 365–1 days before new CV event                               | 3226| 1489 (2314)| 1341 (7119)| 148 (7292)   |
| 0–30 days after new CV event                                 | 3226| 6397 (5382)| 116 (875)  | 6281 (5450)  |
| 0–365 days after new CV event                                | 3226| 9811 (9167)| 1148 (6879)| 8663 (11,482)|
| 366–730 days after new CV event                              | 2465| 2835 (6072)| 1312 (5795)| 1523 (8365)  |
| 731–1095 days after new CV event                              | 2160| 2474 (4841)| 1460 (6305)| 1014 (8005)  |
| Low/unknown risk cohort                                      |    |           |           |              |
| 365–1 days before new CV event                               | 2497| 1029 (2152)| 699 (1473) | 330 (1897)   |
| 0–30 days after new CV event                                 | 2497| 6524 (5616)| 54 (130)   | 6470 (5613)  |
| 0–365 days after new CV event                                | 2497| 8925 (8192)| 579 (857)  | 8346 (8234)  |
| 366–730 days after new CV event                              | 2031| 1905 (4122)| 677 (1359) | 1228 (4320)  |
| 731–1095 days after new CV event                              | 1841| 1771 (4256)| 725 (1819) | 1046 (4663)  |

* p value <0.01 for all incremental costs
| Event type: heart failure | CVD history cohort: mean costs of HRU in € (SD) | CHD risk equivalent cohort: mean costs of HRU in € (SD) | Incremental |
|--------------------------|-----------------------------------------------|-----------------------------------------------|-------------|
|                          | **n** | Cases | Controls | Incremental | **n** | Cases | Controls | Incremental |
| Event type: heart failure |                   |       |         |           |       |       |         |           |
| Event type: ischemic stroke |       |       |         |           |       |       |         |           |
| Event type: myocardial infarction |       |       |         |           |       |       |         |           |
| Event type: transient ischemic attack |       |       |         |           |       |       |         |           |
| Event type: unstable angina pectoris |       |       |         |           |       |       |         |           |
| Event type: revascularization |       |       |         |           |       |       |         |           |

Table 4 Cost of health resource utilization by cohort and event type for cases (matched patients with new cardiovascular events) and controls (matched patients without new cardiovascular events)
world evidence of high quality. The combination of breaking down HRU into categories and into costs over the acute phase, short term, and long term, together with the stratification of patients by risk are further strengths, as this contributes to filling important evidence gaps in the literature.

Apart from the advantages mentioned, this study has some limitations. One of them is the lack of a natural index date for controls. This meant that cases and controls were matched based on their characteristics at study inclusion, not at start of follow-up (i.e. CV event index date) when the comparison of cases and controls actually starts. This discrepancy may have led to matched pairs being less comparable at index date than they were at the time of matching. There was some evidence of this as cases became more comorbid during the time from study inclusion to index than did the controls. Thus, despite the stratification and matching of patients aimed at minimizing bias, there may have been potential confounding variables that were not controlled for in the study.

An additional limitation of the study may arise from the study population selection, as hyperlipidemia patients were included in the study based on filled prescriptions for LLT, rather than diagnoses. This was considered to be the most accurate way of identifying hyperlipidemia patients in Sweden as a diagnosis of hyperlipidemia could have been made prior to the date of first available data. However, patients with LLT prescriptions but without hyperlipidemia may still have been included. Additionally, patients without LLT but prior history of CV events were included in the study in order to capture most patients at high risk of CV events.

Another limitation of the study is that data on healthcare provided by nursing homes and similar by the municipality was not a part of this study. Further, as HRU relating to a CV event was conservatively defined as outpatient care and hospitalizations with an accompanying primary diagnosis of a CV event, it is unlikely that all HRU resulting from a CV event (e.g., rehabilitation, all follow-up visits) were captured in the study. Thus, true healthcare utilization is likely to be underestimated in most cases. Productivity losses due to CV events were also not accounted for in the study. As a previous Swedish study has found that indirect costs are of the same magnitude as the direct costs needed for treatment and rehabilitation [13], only a part of the full societal costs of CV events are captured in this study.

In conclusion, the aim of this retrospective register study was to estimate HRU and associated costs of new CV events in patients with hyperlipidemia or prior events, in the short and longer term. The study demonstrated the high costs of CV events and follow-up care up to 3 years after the CV event and contributes towards filling important gaps in available evidence by providing data on short-term
(1st year) and long-term (up to 3 years) resource use and costs of new CV events for patients with varying CV risk levels, including patients with a history of CVD. The study also presents costs by specific CV event types, which provides insight into the varying economic consequences of different events. These results may serve as an important basis for further health economic analysis to predict the cost-effectiveness of new health technologies that may prevent CVD-related events.

Acknowledgments This study was supported by Amgen, Inc. The authors would like to thank Carly J. Paoli for her help in developing the manuscript. This study was funded by Amgen, Inc.

Conflict of interest Authors S. Hallberg, K.M. Fox, J. Mesterton, J. Banefelt, G. Johansson, L.-A. Levin, and P. Sobocki have received industry sponsored grants from Amgen, Inc. Author S.R. Gandra is employed by Amgen, Inc. and owns stock and/or options in Amgen, Inc.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahimi, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S.G., Pyorala, K., Reiner, Z., Rulope, L., Sans-Menendez, S., Op Reimer, W.S., Weissberg, P., Wood, D., Yarnell, J., Zamorano, J.L., Walma, E., Fitzgerald, T., Cooney, M.T., Dudina, A., Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Funck-Brentano, C., Filipatos, G., Hellemans, I., Kristensen, S.D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J.L., Altiner, A., Bonora, E., Durrington, P.N., Fogard, R., Giampaoli, S., Hemingway, H., Hakim, J., Jordan, S.E., Larsen, M.L., Mancia, G., Manolis, A.J., Orth-Gomer, K., Pedersen, T., Rayner, M., Ryden, L., Sammut, M., Schneiderman, N., Stalenhoef, A.F., Tokgozoglu, L., Wiklund, O., Zampelas, A., European Society of Cardiology (ESC), European Association for Cardiovascular Prevention and Rehabilitation (EACPR), Council on Cardiovascular Nursing, European Association for Study of Diabetes (EASD), International Diabetes Federation Europe (IDF-Europe), European Stroke Initiative (EUSI), International Society of Behavioural Medicine (ISBM), European Society of Hypertension (ESH), Europe WONCA (European Society of General Practice/Family Medicine), European Heart Network (EHN), European Atherosclerosis Society (EAS): European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Group Epidemiol Prev Card Rehabil Exerc Physiol 14(Suppl 2), S1–113 (2007). doi:10.1097/01.hjr.0000277983.23934.c9
2. National Institute for Health and Clinical Excellence: statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease. Technology appraisals, TA94 (2006)
3. Chapman, R.H., Liu, L.Z., Girase, P.G., Straka, R.J.: Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC cardiovascular disorders 11, 11 (2011). doi:10.1186/1471-2256-11-11
4. Ohfeldt, R.L., Gandhi, S.K., Fox, K.M., Bullano, M.F., Davidson, M.: Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J med econ 13(3), 500–507 (2010). doi:10.3111/13696998.2010.506348
5. Duh, M.S., Fulcher, N.M., White, L.A., Jayawant, S.S., Ramamurthy, P., Moyneur, E., Ong, S.H.: Costs associated with cardiovascular events in patients with hypertension in US managed care settings. J Am Soc Hypertens JASH 3(6), 403–415 (2009). doi:10.1016/j.jash.2009.09.001
6. Etemad, L.R., McCollam, P.L.: Total first-year costs of acute coronary syndrome in a managed care setting. J manag care pharm JMCP 11(4), 300–306 (2005)
7. Roggeri, A., Gnawi, R., Dalmasso, M., Rusciani, R., Giammaria, M., Anselmino, M., Roggeri, D.P.: Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis. Crit pathw cardiol 12(4), 204–209 (2013)
8. Luengo-Fernandez, R., Leal, J., Gray, A., Petersen, S., Rayner, M.: Cost of cardiovascular diseases in the United Kingdom. heart 92(10), 1384–1389 (2006). doi:10.1136/hrt.2005.072173
9. Leal, J., Luengo-Fernandez, R., Gray, A., Petersen, S., Rayner, M.: Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27(13), 1610–1619 (2006). doi:10.1093/eurheartj/ehi733
Healthcare costs associated with cardiovascular events… 601

16. Sydöstra sjukvårdsregionen: Prislista för sydöstra sjukvårdsregionen. [online]. http://plus.lj.se/info_files/infosida41089/prislista_2012.pdf (2012). Accessed Oct 2014

17. Norra sjukvårdsregionen: Prislista Norrlands universitetssjukhus för vård och övriga tjänster. [online]. http://www.norrlandstingen.se/wp-content/uploads/2012/11/NUSprislista-2012-utg%C3%A5va-21.xls (2012). Accessed Oct 2014

18. Uppsala-Örebro sjukvårdsregion: Regional prislista. [online]. http://www.svnuppsalaorebro.se/document/prislistor/2012/uppsala12.pdf (2012). Accessed Oct 2014

19. Södra Regionvårdsnämnden: Regionala priser och ersättningar för Södra sjukvårdsregionen 2012. [online]. http://www.skane.se/Upload/Webbplatser/Sodra%20regionvardsnamnden/prislista/2012/hela_prislistan2012.pdf (2012). Accessed 21 Oct 2014

20. Västra sjukvårdsregionen: Utomlänspriser 2012—För vårdtjänster enligt samverkansavtal om hälso- och sjukvård inom Västra sjukvårdsregionen. [online]. http://www.vgregion.se/upload/Regionkan-slierna/HSA/Samverkans%C3%A4mnden/Utoml%C3%A4nsprislista%202012.pdf (2012). Accessed Oct 2014

21. Stockholm-Gotland sjukvårdsregionen: Utmomregionsprislistor är 2012 för Stockholm-Gotland regionen. [online]. http://66.7.199.160/~xthlmgot/wp-content/uploads/2013/06/Bilaga-2-Karolinska-Universitetssjukhuset-Utoml%C3%A4nsprislista-2012-.pdf (2012). Accessed Oct 2014

22. Riksbanken: Räntor & valutakurser. [online]. http://www.riksbank.se/sv/Rantor-och-valutakurser/ (2014). Accessed 21 Oct 2014